Azithromycin in the Treatment of Community-acquired Pneumonia in Children
We observed 3 1 children aged 6 months to 6 years with community-acquired pneumonia, treated as a causal treatment of azithromycin. 20 children treated Azitroks suspension, 1 1 children - Sumamed suspension (control group). Results of the study showed that the efficacy and safety of the drug Azitroks suspension for the treatment of community-acquired pneumonia in children is comparable to the original drug Sumamed suspension that characterizes him as a quality domestic production of generic and can be recommended for wide use in pediatric patients.